Rein Therapeutics Inc share price logo

Rein Therapeutics Inc Share Price

NASDAQ: RNTX

Large Cap

$1.57

+0.02

(+1.29%)

Live

as on

Rein Therapeutics Inc Stock Performance

as on October 31, 2025 at 7:36 pm IST

  • Day's Low

    $1.54
    $1.57
    downward going graph

    1.91%

    Downside

  • 52 Week's Low

    52 Week's High

    $1.04
    $3.5
    downward going graph

    33.76%

    Downside

    122.93%

    Upside

    downward going graph

Rein Therapeutics Inc share price movements today

Previous Close
$1.55
Open
$1.54
Volume
35.5K
Day's Low - High
$1.54 - $1.57
52 Week Low - High
$1.04 - $3.5

Rein Therapeutics Inc Historical Returns

1 Month Return
+ 31.36 %
3 Month Return
+ 33.05 %
1 Year Return
0 %
3 Year Return
0 %
5 Year Return
0 %

Rein Therapeutics Inc Stock Fundamentals & Key Indicators

Check Rein Therapeutics Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$40.2M

EPS (TTM)

-1.01

Dividend Yield

0.00%

PE Ratio (TTM)

0

PEG Ratio

0

Return On Equity TTM

-79.38%

Rein Therapeutics Inc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Rein Therapeutics Inc with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
Rein Therapeutics Inc image
Rein Therapeutics Inc
NA$40.2MNANA0.00%
Insmed Incorporated image
Insmed Incorporated
BUY$41.1B489.62%-16.34-259.82%
Alnylam Pharmaceuticals, Inc. image
Alnylam Pharmaceuticals, Inc.
BUY$63.1B265.59%-505.15-12.96%
Vertex Pharmaceuticals Incorporated image
Vertex Pharmaceuticals Incorporated
BUY$107.0B101.52%29.6731.86%
Regeneron Pharmaceuticals, Inc. image
Regeneron Pharmaceuticals, Inc.
BUY$68.6B20.33%15.6532.13%

Rein Therapeutics Inc Quarterly Profit & Loss

All numbers in Millions USD

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Total Revenue
-
-
-
-
-
-
-
-
Gross Profit
-
-
-
-
-
-
-
0
Operating Income
0
0
0
0
-6
-42
-5
-6
EBITDA
0
0
0
0
0
0
-5
-6
Interest Expense
-
-
-
-
-
-
-
-
Depreciation
0
0
0
0
-
-
-
0
Income Before Tax
0
0
0
0
-5
-42
-5
-6
Income Tax Expense
-
-
-
-
-
0
-1
-
Net Income
0
0
0
0
0
-40
-5
-6
Net Profit Margin
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%

Rein Therapeutics Inc Annual Profit & Loss

All numbers in Millions USD

Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Total Revenue
-
-
-
-
-
Gross Profit
-
-
-
-
0
Operating Income
0
0
0
0
-65
EBITDA
0
0
0
0
-28
Interest Expense
-
-
-
-
-
Depreciation
0
0
0
0
0
Income Before Tax
0
0
0
0
-64
Income Tax Expense
-
-
-
-
-1
Net Income
0
0
0
0
-62
Net Profit Margin
0.00%
0.00%
0.00%
0.00%
0.00%

Rein Therapeutics Inc Quarterly Cash Flow

All numbers in Millions USD

Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Net Income
-1
-1
-7
-7
-8
-5
-40
-5
-6
Operating Cash Flow
-3
-1
-10
-5
-8
-3
-4
-6
-6
Investing Cash Flow
8
0
0
-
-
-
-
-
-
Financing Cash Flow
-
-
15
-
18
0
0
0
4
Change in Cash
5
-1
5
-5
9
-4
-4
-5
-1

Rein Therapeutics Inc Annual Cash Flow

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Net Income
-18
-22
-31
-29
-21
-26
-27
-15
-62
Operating Cash Flow
-15
-20
-27
-26
-20
-23
-24
-19
-22
Investing Cash Flow
0
-38
24
-2
6
-35
26
16
-
Financing Cash Flow
31
50
2
23
15
55
-
15
17
Change in Cash
16
-8
0
-5
1
-4
1
12
-4

Insights on Rein Therapeutics Inc

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 7 days, RNTX stock has moved up by 7.6%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Insmed Incorporated has given 1021.4% return, outperforming this stock by 1082.7%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Insmed Incorporated has given 188.7% return, outperforming this stock by 251.1%

About Rein Therapeutics Inc

Rein Therapeutics, Inc., formerly Aileron Therapeutics, Inc., is a clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-class therapies to address significant unmet medical needs in orphan pulmonary and fibrosis indications. The Company's lead product candidate, LTI-03 (idiopathic pulmonary fibrosis), is a novel, synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. Its second product candidate, LTI-01, is a proenzyme that has completed Phase 1b and Phase 2a clinical trials for the treatment of loculated pleural effusions. LTI-01 has received Orphan Drug Designation in the United States and European Union and Fast Track Designation in the United States. Its pipeline also includes LTI-05 (cystic fibrosis).
OrganisationRein Therapeutics Inc
Headquarters12407 N. Mopac Expy., Austin, TX, United States, 78758
CEODr. James Brian Windsor Ph.D.
E-voting on sharesClick here to vote

Key Management of Rein Therapeutics Inc

Name

Title

Mr. Timothy M. Cunningham CPA, M.B.A.

Interim CFO & Principal Accounting Officer

Dr. Cory M. Hogaboam Ph.D.

Chief Scientific Officer

Ms. Jennifer Faigle

Counsel

Mr. Ron Chen

VP of Finance and Corporate Controller

Dr. James Brian Windsor Ph.D.

CEO, President & Director

FAQs

What is Rein Therapeutics Inc share price today?

Rein Therapeutics Inc share price today is $1.57 as on . Rein Therapeutics Inc share today touched a day high of $1.57 and a low of $1.54.

What is the 52 week high and 52 week low for Rein Therapeutics Inc share?

Rein Therapeutics Inc share touched a 52 week high of $3.5 on and a 52 week low of $1.04 on . Rein Therapeutics Inc stock price today i.e. is trending at $1.57,which is 55.14% down from its 52 week high and 50.96% up from its 52 week low.

What is Rein Therapeutics Inc's market capitalisation today?

Rein Therapeutics Inc market capitalisation is $0.00T as on .

How to invest in Rein Therapeutics Inc Stock (RNTX) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Rein Therapeutics Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Rein Therapeutics Inc Shares that will get you 0.9554 shares as per Rein Therapeutics Inc share price of $1.57 per share as on October 31, 2025 at 7:36 pm IST.

What is the minimum amount required to buy Rein Therapeutics Inc Stock (RNTX) from India?

Indian investors can start investing in Rein Therapeutics Inc (RNTX) shares with as little as ₹88.665 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹886.65 in Rein Therapeutics Inc stock (as per the Rupee-Dollar exchange rate as on ). Based on Rein Therapeutics Inc share’s latest price of $1.57 as on October 31, 2025 at 7:36 pm IST, you will get 6.3694 shares of Rein Therapeutics Inc. Learn more about fractional shares .